D. C. Gauna

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.

J. Pérez-Gracia, U. A. Herranz, Susana Hernando-Polo, 2020, Clinical genitourinary cancer.

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

T. Powles, M. Galsky, A. Gupta, 2020 .

Intravascular disseminated coagulopathy as a debut of metastatic prostate cancer: A case report

L. Paz-Ares, D. C. Gauna, R. M. Kopp, 2017 .

Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

R. Huddart, C. Sternberg, F. Massari, 2019, Annals of Oncology.